Here are five notes:
1. Felix Cheung, MD, associate professor and chief of the division of orthopedic oncology at Joan C Edwards School of Medicine at Marshall University in Huntington, W. Va., performed the surgeries.
2. The patients were treated as part of its U.S. Lightfix clinical trial for the treatment of fractures in the humerus due to metastatic carcinoma.
3. The IlluminOss System uses minimally invasive technology that allows for fracture fixation through patient-specific intramedullary implants with a light-curable polymer contained within a balloon catheter.
4. The IlluminOss System has been successful in the treatment of more than 1,000 patients in Europe, where it is commercially available and has been in clinical use since 2010.
5. IlluminOss Medical is currently enrolling patients at other U.S. surgical sites in the Lightfix clinical trial.
More articles on devices:
45 orthopedic, spine devices receive FDA 510(k) clearance in May 2015
Amendia acquires SpineSelect assets — 5 key notes
Wenzel Spine’s VariLift Interbody Fusion shown effective in published paper — 5 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
